Core Viewpoint - China National Pharmaceutical Group (01177.HK) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd. has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug TRD221, a complement protein modulator intended for the treatment of osteoarthritis [1]. Group 1 - The drug TRD221 is classified as a national Class 1 innovative drug [1]. - The approval from NMPA marks a significant milestone for the company in its drug development pipeline [1]. - The intended use of TRD221 is specifically for osteoarthritis, indicating a focus on addressing this prevalent condition [1].

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Beijing Tide Pharmaceutical Co., has received clinical trial approval from the NMPA for its first-in-class innovative drug TRD221, aimed at treating osteoarthritis [1][2]. Group 1: Company Developments - TRD221 is a complex polysaccharide drug developed in collaboration with the Chinese Academy of Medical Sciences, showcasing good biocompatibility and safety [1]. - The drug acts as a key protein regulator that inhibits the release of inflammatory factors from the complement system, thereby promoting cartilage repair and delaying disease progression [1]. Group 2: Industry Context - Osteoarthritis (OA) is a degenerative disease affecting joint cartilage, with approximately 595 million patients globally in 2020, expected to rise to 642 million by 2050 [2]. - The prevalence of primary OA among individuals over 40 in China has reached 46.3%, with an increasing trend due to an aging population [2]. - Current OA treatments primarily focus on pain relief, with significant unmet clinical needs in disease progression and joint function improvement [2]. - TRD221 has shown dual effects in animal models by alleviating pain symptoms and improving structural damage, indicating its potential as a new treatment option for OA [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TRD221「補體蛋白調節劑」臨床試驗申請獲NMPA批准 注射用TRD221是由北京泰德與中國醫學科學院藥物研究所聯合開發的一款全球首創(First-in-class) 的複雜多糖類藥物。多糖擁有良好的生物相容性和安全性，但由於其作用機制複雜，藥學研究、質 量控制和藥理評價等方面存在諸多挑戰，長期制約著多糖類創新藥的研發進程。TRD221作為一種補 體系統級聯激活的關鍵蛋白調節劑，能夠抑制補體系統激活的炎症因子釋放，阻斷其對軟骨細胞的 直接損傷，調節軟骨細胞的代謝穩態，從而促進軟骨修復，延緩疾病進展。 骨關節炎（OA）是由多種因素引起關節軟骨纖維化、皸裂、潰瘍及脫失的退行性疾病，臨床主要表現 為關節疼痛、畸形和功能障礙。OA不僅嚴重影響患者生活質量，還顯著增加心血管事件、下肢深靜 脈血栓栓 ...

Core Viewpoint - China Biologic Products Holdings (01177.HK) announced that it will hold a board meeting on March 26, 2026, to approve the annual results for the year ending December 31, 2025, and to consider the proposal for the final dividend distribution, if any [1] Group 1 - The board meeting is scheduled for March 26, 2026 [1] - The meeting will focus on approving the annual performance results for the year ending December 31, 2025 [1] - The company will also consider the proposal for the final dividend distribution during this meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 董事會召開通知 香港，二零二六年三月十六日 於本公告日期，本公司董事會包括六位執行董事，即謝其潤女士、謝炳先生、鄭翔玲女士、謝承潤 先生、謝炘先生及田舟山先生，以及五位獨立非執行董事，即陸正飛先生、李大魁先生、魯紅女 士、張魯夫先生及李國棟醫生。 承董事會命 中國生物製藥有限公司 公司秘書 賴娟 中國生物製藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零二六年三月二十六 日（星期四）舉行董事會會議，藉以批准（其中包括）刊發本公司及其附屬公司截至二零二五年十二月 三十一日止年度之年度業績以及考慮建議派發末期股息（如有）。 ...

Group 1 - China Biologic Products (01177.HK) announced that its subsidiary, Chengda Tianqing, has completed the interim analysis of the Phase III clinical study for TQB3454, an IDH1 inhibitor for advanced cholangiocarcinoma with IDH1 mutations, achieving the predefined efficacy thresholds for progression-free survival (PFS) and overall survival (OS) [1] - The study, TQB3454-III-01, is a randomized, double-blind, placebo-controlled, multi-center Phase III trial aimed at evaluating the efficacy and safety of TQB3454 in patients with advanced cholangiocarcinoma who have failed previous treatments [1] - The independent data monitoring committee (IDMC) determined that TQB3454 significantly reduces the risk of disease progression or death compared to the control group, significantly extending both PFS and OS [1] Group 2 - Cholangiocarcinoma (BTC) accounts for approximately 3% of all digestive system tumors, with over 200,000 new cases globally in 2021, and its incidence is on the rise [2] - BTC primarily consists of adenocarcinoma, characterized by high malignancy and poor prognosis, with a five-year survival rate of less than 5% [2] - IDH1 inhibitors are crucial for the precision treatment of cholangiocarcinoma, and currently, there are no approved drugs targeting this pathway in China, indicating a significant unmet clinical need [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 自願公告 TQB3454「IDH1抑制劑」膽道癌III期臨床研究取得陽性結果 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團 附屬公司正大天晴藥業集團股份有限公司（「正大天晴」）自主研發的國家1類創新藥TQB3454「IDH1抑 制劑」治療伴IDH1突變晚期膽道癌III期臨床研究已完成方案預設的期中分析，獨立數據監查委員會 (IDMC)判定主要研究終點無進展生存期(PFS)、總生存期(OS)均達到方案預設的優效界值。本集團已 與中國國家藥品監督管理局藥品審評中心(CDE)就該適應症的上市申請進行溝通，並獲得CDE書面同 意，將於近期遞交上市申請。這是全球第2個、國內第1個IDH1抑制劑在膽道癌取得成功的III期臨床 研究。 1 膽道癌(BTC)主要包括膽管癌和膽囊癌，約佔所有消化系腫瘤的3%，2021年全球新發患者數量超過 20萬，且發病率呈上升趨勢[1 ...

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Changchun Tianqing Pharmaceutical, has received clinical trial approval from the National Medical Products Administration for its innovative drug TQB3205, aimed at treating advanced malignant tumors [1] Group 1: Drug Development - TQB3205 is an oral pan-KRAS inhibitor that effectively suppresses the proliferation of various KRAS-mutant tumor cells [1] - The company plans to accelerate the clinical development of TQB3205 to overcome existing treatment limitations [1] - The goal is to provide new treatment options for a broader range of patients with advanced malignant tumors harboring KRAS mutations [1]

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Chengdu Tianqing Pharmaceutical, has received clinical trial approval from the NMPA for its innovative drug TQB3205, a pan-KRAS inhibitor aimed at treating advanced malignant tumors [1][2] Group 1: Product Development - TQB3205 is an oral pan-KRAS inhibitor that binds with high affinity to various KRAS mutant proteins, inhibiting SOS1-mediated nucleotide exchange and blocking RAS activation, thereby effectively suppressing the proliferation of various KRAS mutant tumor cells [1] - The KRAS gene is the most frequently mutated gene in the RAS family, with approximately 30% of cancer cases associated with RAS gene mutations, and KRAS mutations account for 85% of all RAS mutations, prevalent in pancreatic cancer (90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%) [1] - Currently, five KRAS inhibitors approved globally only target the G12C mutation subtype, highlighting the need for broader coverage of KRAS mutation subtypes [1][2] Group 2: Market Demand and Strategy - The clinical demand in the KRAS field remains unmet, necessitating the development of pan-KRAS inhibitors that can address a wider range of mutation subtypes [2] - The company aims to accelerate the clinical development of TQB3205 to provide new treatment options for patients with advanced malignant tumors harboring various KRAS mutations [2]

Core Insights - China National Pharmaceutical Group's subsidiary, Chengdu Tianqing Pharmaceutical, has received clinical trial approval from the NMPA for TQB3205, a pan-KRAS inhibitor intended for the treatment of advanced malignant tumors [1][2] - TQB3205 is an oral pan-KRAS inhibitor that binds with high affinity to various KRAS mutant proteins, inhibiting SOS1-mediated nucleotide exchange and blocking RAS activation, thereby effectively suppressing the proliferation of various KRAS mutant tumor cells [1] - KRAS mutations are the most frequent in the RAS gene family, with approximately 30% of cancer cases associated with RAS mutations, and KRAS mutations account for 85% of all RAS-related cancers, prevalent in pancreatic cancer (90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%) [1] Development and Market Needs - The company has accelerated the clinical development of TQB3205 to address the unmet clinical needs in the KRAS field, which currently lacks pan-KRAS inhibitors that cover a broader range of mutation subtypes [2] - The company's previously developed KRAS G12C inhibitor, known as Sotorasib (brand name: Anfatin), received NMPA approval for market launch in November 2024, highlighting the ongoing demand for effective treatments in this area [2]